Nymox Pharmaceutical Return on Equity

Nymox Pharmaceutical (NYMX) currently reports a ROE of 116.9%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Nymox Pharmaceutical's ROE history and peer comparisons.

Nymox Pharmaceutical's ROE of 116.9% is higher than the Healthcare sector average of -75.84%. That is roughly 254.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Nymox Pharmaceutical's current 116.9% should be judged against Healthcare norms (sector average: -75.84%) and against NYMX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 116.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Nymox Pharmaceutical, and consider following NYMX for alerts when major investors trade the stock.

Nymox Pharmaceutical is classified in the Healthcare sector. On ROE, it currently shows 116.9% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NYMX with unrelated industries.